Oxford Immunotec Global PLC Stock Price, News & Analysis (NASDAQ:OXFD)

$14.30 0.05 (0.35 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$14.25
Today's Range$14.18 - $14.30
52-Week Range$12.19 - $19.51
Volume42,542 shs
Average Volume107,071 shs
Market Capitalization$365.58 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.17

About Oxford Immunotec Global PLC (NASDAQ:OXFD)

Oxford Immunotec Global PLC logoOxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Diagnostic & Testing Equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780

Debt

Debt-to-Equity Ratio0.38%
Current Ratio4.72%
Quick Ratio4.30%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$86.08 million
Price / Sales4.26
Cash FlowN/A
Price / CashN/A
Book Value$3.02 per share
Price / Book4.74

Profitability

Trailing EPS($2.02)
Net Income$-22,340,000.00
Net Margins-45.74%
Return on Equity-38.42%
Return on Assets-21.18%

Miscellaneous

Employees432
Outstanding Shares25,660,000

Frequently Asked Questions for Oxford Immunotec Global PLC (NASDAQ:OXFD)

What is Oxford Immunotec Global PLC's stock symbol?

Oxford Immunotec Global PLC trades on the NASDAQ under the ticker symbol "OXFD."

How were Oxford Immunotec Global PLC's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its quarterly earnings data on Tuesday, August, 2nd. The company reported ($0.29) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.04. The company earned $19.20 million during the quarter, compared to analysts' expectations of $18.10 million. Oxford Immunotec Global PLC had a negative return on equity of 38.42% and a negative net margin of 45.74%. The firm's revenue for the quarter was up 34.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.33) earnings per share. View Oxford Immunotec Global PLC's Earnings History.

When will Oxford Immunotec Global PLC make its next earnings announcement?

Oxford Immunotec Global PLC is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Oxford Immunotec Global PLC.

Where is Oxford Immunotec Global PLC's stock going? Where will Oxford Immunotec Global PLC's stock price be in 2017?

4 brokerages have issued 12 month target prices for Oxford Immunotec Global PLC's stock. Their forecasts range from $19.00 to $21.00. On average, they expect Oxford Immunotec Global PLC's stock price to reach $19.75 in the next year. View Analyst Ratings for Oxford Immunotec Global PLC.

What are Wall Street analysts saying about Oxford Immunotec Global PLC stock?

Here are some recent quotes from research analysts about Oxford Immunotec Global PLC stock:

  • 1. According to Zacks Investment Research, "Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company's first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. " (11/4/2017)
  • 2. BTIG Research analysts commented, "This evening bluebird provided a 1Q update via press release (no conference call, as usual). Following an April meeting with the EMA, BLUE updated its EU regulatory strategy noting that it anticipates filing for conditional approval in non-B0/B0 patients on the basis of the ongoing Northstar and HGB-205 studies, plus data available from the ongoing Northstar-2 at the time of filing. Amount of follow up needed from Northstar and HGB-205 is TBD (data dependent and discussions with the EMA are ongoing). On the catalyst front, previously announced timelines are intact, and 2017 is looking to be a busy year for bluebird. Overall, we remain encouraged with the company’s continued progress across multiple clinical programs involving its potentially transformative gene therapy and CAR-T platforms. Maintain OW." (5/4/2017)

Who are some of Oxford Immunotec Global PLC's key competitors?

Who are Oxford Immunotec Global PLC's key executives?

Oxford Immunotec Global PLC's management team includes the folowing people:

  • Richard A. Sandberg, Independent Chairman of the Board (Age 74)
  • Peter James Wrighton-Smith Ph.D., Chief Executive Officer, Director (Age 42)
  • Richard M. Altieri, Chief Financial Officer (Age 57)
  • Stefan C. Linn, Chief Operating Officer (Age 51)
  • Peter Edwardson Ph.D., Senior Vice President & Head of Blood Screening (Age 52)
  • Elizabeth M. Keiley, Vice President, General Counsel (Age 51)
  • Jeff R. Schroeder, Chief Commercial Officer (Age 55)
  • Richard J. Wenstrup M.D., Chief Medical Officer (Age 64)
  • Ronald A. Andrews Jr., Director (Age 57)
  • Patrick J. Balthrop Sr., Director (Age 60)

Who owns Oxford Immunotec Global PLC stock?

Oxford Immunotec Global PLC's stock is owned by many different of institutional and retail investors. Top institutional investors include Alyeska Investment Group L.P. (5.28%), RTW Investments LP (4.02%), Wasatch Advisors Inc. (2.24%), Cortina Asset Management LLC (2.20%), Granahan Investment Management Inc. MA (1.95%) and Perceptive Advisors LLC (1.81%). Company insiders that own Oxford Immunotec Global PLC stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global PLC.

Who sold Oxford Immunotec Global PLC stock? Who is selling Oxford Immunotec Global PLC stock?

Oxford Immunotec Global PLC's stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC and Keybank National Association OH. Company insiders that have sold Oxford Immunotec Global PLC company stock in the last year include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global PLC.

Who bought Oxford Immunotec Global PLC stock? Who is buying Oxford Immunotec Global PLC stock?

Oxford Immunotec Global PLC's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Alyeska Investment Group L.P., RTW Investments LP, Stonepine Capital Management LLC, Columbus Circle Investors, Wasatch Advisors Inc., EAM Investors LLC and Cortina Asset Management LLC. View Insider Buying and Selling for Oxford Immunotec Global PLC.

How do I buy Oxford Immunotec Global PLC stock?

Shares of Oxford Immunotec Global PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oxford Immunotec Global PLC's stock price today?

One share of Oxford Immunotec Global PLC stock can currently be purchased for approximately $14.30.

How big of a company is Oxford Immunotec Global PLC?

Oxford Immunotec Global PLC has a market capitalization of $365.58 million and generates $86.08 million in revenue each year. The company earns $-22,340,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. Oxford Immunotec Global PLC employs 432 workers across the globe.

How can I contact Oxford Immunotec Global PLC?

Oxford Immunotec Global PLC's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]


MarketBeat Community Rating for Oxford Immunotec Global PLC (OXFD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  110 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Oxford Immunotec Global PLC (NASDAQ:OXFD)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.142.332.172.33
Ratings Breakdown: 3 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.75$22.00$21.33$19.00
Price Target Upside: 49.06% upside30.80% upside32.26% upside30.32% upside

Consensus Price Target History for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Price Target History for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Analysts' Ratings History for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/31/2017BTIG ResearchSet Price TargetBuy$21.00N/AView Rating Details
11/1/2017Robert W. BairdReiterated RatingBuy$20.00N/AView Rating Details
10/31/2017Piper Jaffray CompaniesLower Price TargetOverweight$26.00 -> $19.00N/AView Rating Details
9/28/2017Cowen IncReiterated RatingBuy$19.00HighView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Earnings by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Earnings History by Quarter for Oxford Immunotec Global PLC (NASDAQ OXFD)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018        
8/1/2017Q2 2017($0.32)($0.32)$25.05 million$26.10 millionViewListenView Earnings Details
5/2/20173/31/2017($0.35)($0.36)$21.17 million$21.51 millionViewListenView Earnings Details
3/1/201712/31/2016($0.39)($0.22)$23.06 million$23.71 millionViewListenView Earnings Details
11/1/2016Q316($0.33)($0.18)$24.79 million$26.10 millionViewN/AView Earnings Details
8/2/2016Q216($0.33)($0.29)$18.10 million$19.20 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.32)$16.96 million$17.10 millionViewN/AView Earnings Details
3/1/2016Q415($0.28)($0.29)$16.34 million$16.00 millionViewN/AView Earnings Details
11/3/2015Q315($0.25)($0.20)$17.31 million$17.90 millionViewN/AView Earnings Details
8/4/2015Q215($0.34)($0.33)$14.04 million$14.30 millionViewN/AView Earnings Details
5/5/2015Q115($0.33)($0.31)$13.35 million$13.80 millionViewN/AView Earnings Details
3/3/2015Q414($0.44)($0.39)$11.93 million$12.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.38)($0.35)$12.85 million$13.30 millionViewN/AView Earnings Details
8/5/2014Q214($0.20)($0.36)$11.39 million$11.80 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.18)$11.64 million$12.30 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.38)$9.28 million$10.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Oxford Immunotec Global PLC (NASDAQ:OXFD)
Current Year EPS Consensus Estimate: $-2.11 EPS
Next Year EPS Consensus Estimate: $-1.02 EPS

Dividends

Dividend History for Oxford Immunotec Global PLC (NASDAQ:OXFD)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Oxford Immunotec Global PLC (NASDAQ OXFD)

Insider Ownership Percentage: 8.11%
Institutional Ownership Percentage: 80.57%
Insider Trades by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)
Insider Trades by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Insider Trades by Quarter for Oxford Immunotec Global PLC (NASDAQ OXFD)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Richard A SandbergDirectorSell3,000$13.35$40,050.00View SEC Filing  
10/2/2017Peter Wrighton-SmithCEOSell55,000$16.78$922,900.00View SEC Filing  
9/1/2017Richard A SandbergDirectorSell3,000$15.82$47,460.00View SEC Filing  
8/15/2017Peter EdwardsonCOOSell9,739$16.14$157,187.46View SEC Filing  
8/7/2017Peter EdwardsonCOOSell22,371$17.70$395,966.70View SEC Filing  
7/6/2017Peter Wrighton-SmithCEOSell27,168$15.94$433,057.92View SEC Filing  
7/5/2017Peter Wrighton-SmithCEOSell32,832$16.58$544,354.56View SEC Filing  
6/28/2017Peter Wrighton-SmithCEOSell30,000$16.06$481,800.00View SEC Filing  
6/15/2017Elizabeth M KeileyVPSell4,085$15.01$61,315.85View SEC Filing  
5/15/2017Peter EdwardsonCOOSell10,000$14.66$146,600.00View SEC Filing  
5/10/2017Richard A SandbergDirectorSell3,000$14.40$43,200.00View SEC Filing  
5/9/2017Jeff R SchroederInsiderSell40,000$14.14$565,600.00View SEC Filing  
4/3/2017Peter Wrighton-SmithCEOSell30,000$15.43$462,900.00View SEC Filing  
4/3/2017Richard A SandbergDirectorSell3,000$15.47$46,410.00View SEC Filing  
3/20/2017Elizabeth M KeileyVPSell3,000$16.05$48,150.00View SEC Filing  
2/6/2017Peter Wrighton-SmithCEOSell25,000$13.36$334,000.00View SEC Filing  
12/16/2016Peter Wrighton-SmithCEOSell7,052$15.07$106,273.64View SEC Filing  
12/5/2016Peter Wrighton-SmithCEOSell1,140$15.00$17,100.00View SEC Filing  
12/2/2016Peter Wrighton-SmithCEOSell61,808$15.00$927,120.00View SEC Filing  
11/8/2016Richard A SandbergDirectorSell12,000$14.17$170,040.00View SEC Filing  
11/18/2015Richard A. SandbergDirectorSell5,000$13.48$67,400.00View SEC Filing  
11/17/2015Richard A. SandbergDirectorSell5,000$13.00$65,000.00View SEC Filing  
6/16/2015Lifesciences I L.P. ClarusMajor ShareholderSell41,230$14.30$589,589.00View SEC Filing  
6/15/2015Lifesciences I L.P. ClarusMajor ShareholderSell1,529$14.27$21,818.83View SEC Filing  
6/12/2015Lifesciences I L.P. ClarusMajor ShareholderSell31,598$14.27$450,903.46View SEC Filing  
6/10/2015Lifesciences I L.P. ClarusMajor ShareholderSell24,649$14.28$351,987.72View SEC Filing  
6/9/2015Lifesciences I L.P. ClarusMajor ShareholderSell13,000$14.26$185,380.00View SEC Filing  
6/8/2015Lifesciences I L.P. ClarusMajor ShareholderSell2,662$14.25$37,933.50View SEC Filing  
6/3/2015Lifesciences I L.P. ClarusMajor ShareholderSell36,474$14.29$521,213.46View SEC Filing  
6/1/2015Richard A SandbergDirectorSell3,000$14.14$42,420.00View SEC Filing  
3/23/2015Lifesciences I L.P. ClarusMajor ShareholderSell53,415$14.49$773,983.35View SEC Filing  
3/19/2015Lifesciences I L.P. ClarusMajor ShareholderSell154,319$14.65$2,260,773.35View SEC Filing  
1/14/2015Richard A SandbergDirectorSell3,000$14.00$42,000.00View SEC Filing  
12/5/2014Patricia RandallDirectorSell5,000$12.06$60,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Oxford Immunotec Global PLC (NASDAQ OXFD)

Source:
DateHeadline
Oxford Immunotec: Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare ConferenceOxford Immunotec: Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference
www.finanznachrichten.de - November 22 at 6:30 AM
BRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech ABBRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB
www.reuters.com - November 22 at 6:30 AM
Zacks: Brokerages Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $25.88 MillionZacks: Brokerages Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $25.88 Million
www.americanbankingnews.com - November 14 at 9:50 AM
Zacks: Analysts Expect Oxford Immunotec Global PLC (OXFD) Will Announce Earnings of -$0.34 Per ShareZacks: Analysts Expect Oxford Immunotec Global PLC (OXFD) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - November 12 at 9:30 AM
Oxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Hold" by BrokeragesOxford Immunotec Global PLC (OXFD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 11 at 1:46 AM
Oxford Immunotec to Present at the Jefferies 2017 London Healthcare ConferenceOxford Immunotec to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 10 at 9:33 AM
ETFs with exposure to Oxford Immunotec Global Plc : November 6, 2017ETFs with exposure to Oxford Immunotec Global Plc : November 6, 2017
finance.yahoo.com - November 7 at 8:20 AM
Oxford Immunotec Global PLC (OXFD) Downgraded by Zacks Investment Research to SellOxford Immunotec Global PLC (OXFD) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - November 4 at 10:13 AM
Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 8:39 AM
Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 8:39 AM
Oxford Immunotec Global PLC (OXFD) Director Richard A. Sandberg Sells 3,000 SharesOxford Immunotec Global PLC (OXFD) Director Richard A. Sandberg Sells 3,000 Shares
www.americanbankingnews.com - November 2 at 6:24 PM
Oxford Immunotec Global PLC (OXFD) Given a $21.00 Price Target by BTIG Research AnalystsOxford Immunotec Global PLC (OXFD) Given a $21.00 Price Target by BTIG Research Analysts
www.americanbankingnews.com - November 1 at 1:22 PM
Edited Transcript of OXFD earnings conference call or presentation 31-Oct-17 12:00pm GMTEdited Transcript of OXFD earnings conference call or presentation 31-Oct-17 12:00pm GMT
finance.yahoo.com - November 1 at 7:23 AM
ValuEngine Downgrades Oxford Immunotec Global PLC (OXFD) to SellValuEngine Downgrades Oxford Immunotec Global PLC (OXFD) to Sell
www.americanbankingnews.com - October 31 at 10:34 PM
Oxford Immunotec Global PLC (OXFD) Releases  Earnings Results, Misses Estimates By $0.25 EPSOxford Immunotec Global PLC (OXFD) Releases Earnings Results, Misses Estimates By $0.25 EPS
www.americanbankingnews.com - October 31 at 4:56 PM
Oxford Immunotec Global PLC (OXFD) PT Lowered to $19.00 at Piper Jaffray CompaniesOxford Immunotec Global PLC (OXFD) PT Lowered to $19.00 at Piper Jaffray Companies
www.americanbankingnews.com - October 31 at 11:54 AM
Oxford Immunotec Global PLC to Host Earnings CallOxford Immunotec Global PLC to Host Earnings Call
finance.yahoo.com - October 31 at 7:35 AM
Oxford Immunotec Reports Third Quarter 2017 Financial ResultsOxford Immunotec Reports Third Quarter 2017 Financial Results
finance.yahoo.com - October 31 at 7:35 AM
Oxford Immunotec Global PLC (OXFD) Expected to Post Quarterly Sales of $30.11 MillionOxford Immunotec Global PLC (OXFD) Expected to Post Quarterly Sales of $30.11 Million
www.americanbankingnews.com - October 25 at 6:20 PM
Oxford Immunotec Global PLC (OXFD) Set to Announce Quarterly Earnings on TuesdayOxford Immunotec Global PLC (OXFD) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 24 at 8:17 AM
Oxford Immunotec Global Plc – Value Analysis (NASDAQ:OXFD) : October 23, 2017Oxford Immunotec Global Plc – Value Analysis (NASDAQ:OXFD) : October 23, 2017
finance.yahoo.com - October 24 at 8:15 AM
Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : October 20, 2017Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : October 20, 2017
finance.yahoo.com - October 21 at 7:49 AM
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31,Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31,
www.nasdaq.com - October 17 at 3:48 PM
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017
finance.yahoo.com - October 17 at 3:48 PM
Oxford Immunotec Global PLC (OXFD) Given Average Rating of "Hold" by AnalystsOxford Immunotec Global PLC (OXFD) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 17 at 2:52 AM
Oxford Immunotec Global PLC (OXFD) Upgraded to "Hold" at Zacks Investment ResearchOxford Immunotec Global PLC (OXFD) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 8 at 9:56 PM
 Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $30.11 Million Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $30.11 Million
www.americanbankingnews.com - October 6 at 6:44 AM
Oxford Immunotec Global PLC (OXFD) CEO Sells $922,900.00 in StockOxford Immunotec Global PLC (OXFD) CEO Sells $922,900.00 in Stock
www.americanbankingnews.com - October 4 at 7:40 PM
Oxford Immunotec Global PLC (OXFD) Expected to Announce Earnings of -$0.25 Per ShareOxford Immunotec Global PLC (OXFD) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - October 4 at 2:36 PM
Oxford Immunotec Global PLC (OXFD) Receives Buy Rating from Cowen and CompanyOxford Immunotec Global PLC (OXFD) Receives Buy Rating from Cowen and Company
www.americanbankingnews.com - September 28 at 9:32 PM
Oxford Immunotec Global PLC (OXFD) Coverage Initiated by Analysts at BTIG ResearchOxford Immunotec Global PLC (OXFD) Coverage Initiated by Analysts at BTIG Research
www.americanbankingnews.com - September 28 at 8:20 PM
Benzingas Top Upgrades, Downgrades For September 28, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For September 28, 2017 - Benzinga
www.benzinga.com - September 28 at 7:27 PM
Oxford loses bid to prevent Qiagen from selling QFT-Plus TB test before patent infringement trial, but likely to ... - Seeking AlphaOxford loses bid to prevent Qiagen from selling QFT-Plus TB test before patent infringement trial, but likely to ... - Seeking Alpha
seekingalpha.com - September 28 at 7:27 PM
Oxford Immunotec Announces Update in Patent Infringement Litigation - GlobeNewswire (press release)Oxford Immunotec Announces Update in Patent Infringement Litigation - GlobeNewswire (press release)
globenewswire.com - September 28 at 7:27 PM
Oxford Immunotec Global PLC (OXFD) Given Consensus Rating of "Hold" by AnalystsOxford Immunotec Global PLC (OXFD) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - September 22 at 2:34 AM
Head to Head Analysis: Oxford Immunotec Global PLC (OXFD) and Varex Imaging (VREX)Head to Head Analysis: Oxford Immunotec Global PLC (OXFD) and Varex Imaging (VREX)
www.americanbankingnews.com - September 11 at 2:18 PM
Oxford Immunotec Global PLC (OXFD) Director Sells $47,460.00 in StockOxford Immunotec Global PLC (OXFD) Director Sells $47,460.00 in Stock
www.americanbankingnews.com - September 5 at 8:32 PM
Contrasting VAREX IMAGING (VREX) & Oxford Immunotec Global PLC (OXFD)Contrasting VAREX IMAGING (VREX) & Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - September 1 at 10:34 AM
Oxford Immunotec to Present at the Baird 2017 Global Healthcare ConferenceOxford Immunotec to Present at the Baird 2017 Global Healthcare Conference
finance.yahoo.com - August 31 at 8:30 AM
-$0.25 Earnings Per Share Expected for Oxford Immunotec Global PLC (OXFD) This Quarter-$0.25 Earnings Per Share Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - August 28 at 10:40 AM
Oxford Immunotec Global PLC (OXFD) Receives Consensus Rating of "Hold" from BrokeragesOxford Immunotec Global PLC (OXFD) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 28 at 2:36 AM
Cowen and Company Lowers Oxford Immunotec Global PLC (OXFD) Price Target to $19.00Cowen and Company Lowers Oxford Immunotec Global PLC (OXFD) Price Target to $19.00
www.americanbankingnews.com - August 17 at 4:20 PM
Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : August 16, 2017Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : August 16, 2017
finance.yahoo.com - August 17 at 6:39 AM
Oxford Immunotec Global PLC (OXFD) COO Peter Edwardson Sells 9,739 SharesOxford Immunotec Global PLC (OXFD) COO Peter Edwardson Sells 9,739 Shares
www.americanbankingnews.com - August 16 at 8:46 PM
Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary SharesOxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares
finance.yahoo.com - August 16 at 6:34 AM
Oxford Immunotec (OXFD) to Sell 2.5M Ordinary SharesOxford Immunotec (OXFD) to Sell 2.5M Ordinary Shares
www.streetinsider.com - August 15 at 6:03 AM
Oxford Immunotec (OXFD) to Sell 2.5M Ordinary SharesOxford Immunotec (OXFD) to Sell 2.5M Ordinary Shares
www.streetinsider.com - August 15 at 6:03 AM
Oxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary SharesOxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary Shares
finance.yahoo.com - August 15 at 6:03 AM
Oxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary SharesOxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary Shares
finance.yahoo.com - August 15 at 6:03 AM
Alphatec Holdings (ATEC) & Oxford Immunotec Global PLC (OXFD) Critical ComparisonAlphatec Holdings (ATEC) & Oxford Immunotec Global PLC (OXFD) Critical Comparison
www.americanbankingnews.com - August 14 at 4:22 AM

Social Media

Financials

Chart

Oxford Immunotec Global PLC (NASDAQ OXFD) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.